Compare CSW & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSW | MIRM |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.2B |
| IPO Year | N/A | 2019 |
| Metric | CSW | MIRM |
|---|---|---|
| Price | $307.24 | $78.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $309.25 | $92.45 |
| AVG Volume (30 Days) | 174.8K | ★ 813.7K |
| Earning Date | 01-29-2026 | 11-04-2025 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | ★ 15.78 | N/A |
| EPS | ★ 8.52 | N/A |
| Revenue | ★ $964,795,000.00 | $471,794,000.00 |
| Revenue This Year | $25.92 | $53.78 |
| Revenue Next Year | $16.37 | $19.91 |
| P/E Ratio | $36.05 | ★ N/A |
| Revenue Growth | 14.87 | ★ 53.66 |
| 52 Week Low | $230.45 | $36.88 |
| 52 Week High | $401.02 | $82.58 |
| Indicator | CSW | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 62.89 |
| Support Level | $301.77 | $63.23 |
| Resistance Level | $317.51 | $82.58 |
| Average True Range (ATR) | 10.69 | 3.74 |
| MACD | -1.99 | 1.62 |
| Stochastic Oscillator | 52.24 | 81.03 |
CSW Industrials Inc is a diversified industrial growth company with well-established, scalable platforms and domain expertise across three segments, Contractor Solutions, Engineered Building Solutions, and Specialized Reliability Solutions. The company's Contractor Solutions segment involves manufacturing efficient and performance-enhancing products for residential and commercial HVAC/R and plumbing applications, which are designed for professional end-use customers. Majority of the company revenue is generated from Contractor Solutions segment from U.S. markets.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.